<DOC>
	<DOCNO>NCT02501161</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , North America South America . The purpose compare long-term glycaemic control insulin degludec/liraglutide ( IDegLira ) versus insulin glargine ( IGlar ) insulin naïve subject type 2 diabetes mellitus inadequately controlled oral anti diabetic .</brief_summary>
	<brief_title>A 104 Week Clinical Trial Comparing Long Term Glycaemic Control Insulin Degludec/Liraglutide ( IDegLira ) Versus Insulin Glargine Therapy Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female , age great equal 18 year time signing informed consent Subjects diagnose type 2 diabetes mellitus HbA1c 7.011.0 % ( inclusive ) ( 5397 mmol/mol ) central laboratory analysis Body mass index great equal 20 kg/m^2 Insulin naïve subject ; however short term insulin treatment maximum 14 day prior day screen allow , prior insulin treatment gestational diabetes Stable daily dose ( ) include follow antidiabetic drug ( ) /regimens within 90 day prior day screening : ) Biguanides ( metformin great equal 1500 mg maximum tolerate dose document subject medical record ) , b ) Other OAD ( ) allow : sulphonylurea , glinides , pioglitazone , DPP4inhibitors ( great equal half maximum approve dose accord local label maximum tolerate dose documented subject medical record ) Screening calcitonin great equal 50 ng/L Renal impairment estimate Glomerular Filtration Rate ( eGFR ) less 60 ml/min/1.73 m^2 per CKDEPI value define listed classification CKDEPI use IDMS serum creatinine measurement day screen Impaired liver function , define ALAT ASAT great equal 2.5 time upper limit normal Family personal history Multiple Endocrine Neoplasia Type 2 Medullary Thyroid Carcinoma History pancreatitis ( acute chronic ) Treatment medication indication diabetes obesity state inclusion criterion period 90 day day screen Anticipated initiation change concomitant medication 14 consecutive day frequent basis know affect weight glucose metabolism ( e.g . orlistat , thyroid hormone , corticosteroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>